Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease

Neural Plasticity

Volumn 2015, Issue , 2015, Pages

  Siwek, Magdalena Elisabeth ^a   Müller, Ralf ^b   Henseler, Christina ^a   Trog, Astrid ^c   Lundt, Andreas ^a   Wormuth, Carola ^a   Broich, Karl ^a   Ehninger, Dan ^d   Weiergräber, Marco ^a   Papazoglou, Anna ^a  

^a Federal Institute for Drugs and Medical Devices   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE; PHOSPHOLIPASE C DELTA 4; TRANSCRIPTOME; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HIPPOCAMPUS THETA RHYTHM; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OSCILLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA PROBE; SPIKE WAVE; TONIC CLONIC SEIZURE; UPREGULATION; VIDEORECORDING; WILD TYPE MOUSE; ANIMAL; BRAIN CORTEX; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; FEMALE; GENETICS; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; PATHOPHYSIOLOGY; SEIZURE; THETA RHYTHM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PRESENILIN-1; SEIZURES; THETA RHYTHM;

EID: 84928391102     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2015/781731     Document Type: Article

References (97)

1. L. Scott, J. Feng, T. Kiss et al. , "Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic mice," Neurobiology of Aging, vol. 33, no. 7, pp. 1481. e13-1481. e23, 2012.
2. H. Yamaguchi, S. Hirai, M. Morimatsu, M. Shoji, and Y. Nakazato, "Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain," Acta Neuropathologica, vol. 77, no. 3, pp. 314-319, 1989.
3. D. J. Selkoe, "Alzheimers disease is a synaptic failure," Science, vol. 298, no. 5594, pp. 789-791, 2002.
4. D. J. Selkoe and D. Schenk, "Alzheimers disease: molecular understanding predicts amyloid-based therapeutics," Annual Review of Pharmacology and Toxicology, vol. 43, pp. 545-584, 2003.
5. K. H. Ashe, "Learning and memory in transgenic mice modeling Alzheimers disease," Learning andMemory, vol. 8, no. 6, pp. 301-308, 2001.
6. J. L. Eriksenand C. G. Janus, "Plaques, tangles, andmemory loss in mousemodels of neurodegeneration," Behavior Genetics, vol. 37, no. 1, pp. 79-100, 2007.
7. G. G. Glenner and C. W. Wong, "Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," Biochemical and Biophysical Research Communications, vol. 120, no. 3, pp. 885-890, 1984.
8. G. G. Glenner, C. W. Wong,V. Quaranta, and E. D. Eanes, "The amyloid deposits inAlzheimers disease: their nature and pathogenesis," Applied Pathology, vol. 2, no. 6, pp. 357-369, 1984.
9. M. Ohno, S. L. Cole, M. Yasvoina et al. , "BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice," Neurobiology of Disease, vol. 26, no. 1, pp. 134-145, 2007.
10. K. Duff and F. Suleman, "Transgenic mouse models of Alzheimers disease: how useful have they been for therapeutic development?" Briefings in Functional Genomics and Proteomics, vol. 3, no. 1, pp. 47-59, 2004.
11. I. Torres-Aleman, "Toward a comprehensive neurobiology of IGF-I," Developmental Neurobiology, vol. 70, no. 5, pp. 384-396, 2010.
12. L. Devi and M. Ohno, "Deletion of the eIF2α kinase GCN2 fails to rescue the memory decline associated with Alzheimers disease," PLoS ONE, vol. 8, no. 10, Article IDe77335, 2013.
13. S. Sinha, J. P. Anderson,R. Barbour et al. , "Purificationandcloning of amyloid precursor protein β-secretase from human brain," Nature, vol. 402, no. 6761, pp. 537-540, 1999.
14. R. Vassar, B. D. Bennett, S. Babu-Khanet al. , "β-Secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE," Science, vol. 286, no. 5440, pp. 735-741, 1999.
15. H. Oakley, S. L. Cole, S. Logan et al. , "Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimers disease mutations: potential factors in amyloid plaque formation," The Journal of Neuroscience, vol. 26, no. 40, pp. 10129-10140, 2006.
16. M. Ohno, E. A. Sametsky, L. H. Younkin et al. , "BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimers disease," Neuron, vol. 41, no. 1, pp. 27-33, 2004.
17. N. Crouzin, K. Baranger,M. Cavalier et al. , "Area-specific alterations of synaptic plasticity in the 5XFAD mouse model of Alzheimers disease: dissociation between somatosensory cortex and hippocampus," PLoS ONE, vol. 8, no. 9, Article ID e74667, 2013.
18. D. Games, D. Adams, R. Alessandrini et al. , "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, vol. 373, no. 6514, pp. 523-527, 1995.
19. E. M. Rockenstein, L. McConlogue, H. Tan, M. Power, E. Masliah, and L. Mucke, "Levels and alternative splicing of amyloid βprotein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimers disease," The Journal of Biological Chemistry, vol. 270, no. 47, pp. 28257-28267, 1995.
20. R. Goutagny and S. Krantic, "Hippocampal oscillatory activity in Alzheimers disease: toward the identification of early biomarkers?" Aging and Disease, vol. 4, no. 3, pp. 134-140, 2013.
21. S. Jawhar, A. Trawicka, C. Jenneckens, T. A. Bayer, and O. Wirths, "Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFADmousemodel ofAlzheimers disease," Neurobiology of Aging, vol. 33, no. 1, pp. 196. e29-196. e40, 2012.
22. C. Casas,N. Sergeant, J.-M. Itier et al. , "Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model," The American Journal of Pathology, vol. 165, no. 4, pp. 1289-1300, 2004.
23. W. A. Eimer and R. Vassar, "Neuron loss in the 5XFAD mouse model of Alzheimers disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation," Molecular Neurodegeneration, vol. 8, article 29, 2013.
24. C. C. Kaczorowski and J. F. Disterhoft, "Memory deficits are associated with impaired ability tomodulate neuronal excitability in middle-aged mice," Learning and Memory, vol. 16, no. 6, pp. 362-366, 2009.
25. I. Hong, T. Kang, Y. Yoo et al. , "Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimers disease pathology," Journal of Alzheimers Disease, vol. 36, no. 2, pp. 321-334, 2013.
26. K. H. Kim, M. Moon, S.-B. Yu, I. Mook-Jung, and J.-I. Kim, "RNA-Seq analysis of frontal cortex and cerebellum from 5XFADmice at early stage of disease pathology," Journal of Alzheimers Disease, vol. 29, no. 4, pp. 793-808, 2012.
27. P. J. Blanchet, "Antipsychotic drug-induced movement disorders," Canadian Journal of Neurological Sciences, vol. 30, supplement 1, pp. S101-S107, 2003.
28. D. Martino and G. Giovannoni, "Antibasal ganglia antibodies and their relevance tomovement disorders," Current Opinion in Neurology, vol. 17, no. 4, pp. 425-432, 2004.
29. J. J. Palop, J. Chin, and L. Mucke, "A network dysfunction perspective on neurodegenerative diseases," Nature, vol. 443, no. 7113, pp. 768-773, 2006.
30. J. J. Palop and L. Mucke, "Epilepsy and cognitive impairments in alzheimer disease," Archives of Neurology, vol. 66, no. 4, pp. 435-440, 2009.
31. J. J. Palop, J. Chin, E. D. Roberson et al. , "Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimers disease," Neuron, vol. 55, no. 5, pp. 697-711, 2007.
32. G. Buzsaki, "Theta oscillations in the hippocampus," Neuron, vol. 33, no. 3, pp. 325-340, 2002.
33. L. V. Colom, "Septal networks: relevance to theta rhythm, epilepsy and Alzheimers disease," Journal of Neurochemistry, vol. 96, no. 3, pp. 609-623, 2006.
34. J. Chin and H. E. Scharfman, "Shared cognitive and behavioral impairments in epilepsy and Alzheimers disease and potential underlying mechanisms," Epilepsy and Behavior, vol. 26, no. 3, pp. 343-351, 2013.
35. R. Minkeviciene, S. Rheims, M. B. Dobszay et al. , "Amyloid induced neuronal hyperexcitability triggers progressive epilepsy-induced neuronal hyperexcitability triggers progressive epilepsy," The Journal of Neuroscience, vol. 29, no. 11, pp. 3453-3462, 2009.
36. L. Verret, E. O. Mann, G. B. Hang et al. , "Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model," Cell, vol. 149, no. 3, pp. 708-721, 2012.
37. M. F. Mendez and G. T. H. Lim, "Seizures in elderly patients with dementia: epidemiology and management," Drugs and Aging, vol. 20, no. 11, pp. 791-803, 2003.
38. A. J. Larner, "Epileptic seizures in ADpatients," NeuroMolecular Medicine, vol. 12, no. 1, pp. 71-77, 2010.
39. N. Scarmeas, L. S. Honig, H. Choi et al. , "Seizures in Alzheimer disease: who, when, and how common?" Archives of Neurology, vol. 66, no. 8, pp. 992-997, 2009.
40. J. H. Morrison and P. R. Hof, "Life and death of neurons in the aging brain," Science, vol. 278, no. 5337, pp. 412-419, 1997.
41. J. L. Price, A. I. Ko, M. J. Wade, S. K. Tsou, D. W. McKeel, and J. C. Morris, "Neuron number in the entorhinal cortex and CA1 in preclinical alzheimer disease," Archives of Neurology, vol. 58, no. 9, pp. 1395-1402, 2001.
42. R. D. Terry, E. Masliah, D. P. Salmon et al. , "Physical basis of cognitive alterations in Alzheimers disease: synapse loss is the major correlate of cognitive impairment," Annals of Neurology, vol. 30, no. 4, pp. 572-580, 1991.
43. W. A. Hauser, M. L. Morris, L. L. Heston, and V. E. Anderson, "Seizures and myoclonus in patients with Alzheimers disease," Neurology, vol. 36, no. 9, pp. 1226-1230, 1986.
44. M. F. Romanelli, J. C. Morris, K. Ashkin, and L. A. Coben, "Advanced Alzheimers disease is a risk factor for late-onset seizures," Archives of Neurology, vol. 47, no. 8, pp. 847-850, 1990.
45. D. S. Auld, T. J. Kornecook, S. Bastianetto, and R. Quirion, "Alzheimers disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies," Progress in Neurobiology, vol. 68, no. 3, pp. 209-245, 2002.
46. K. M. Cullen, "Perivascular astrocytes within Alzheimers disease plaques," NeuroReport, vol. 8, no. 8, pp. 1961-1966, 1997.
47. J. Palhalmi, O. Paulsen, T. F. Freund, and N. Hajos, "Distinct properties of carbachol-and DHPG-induced network oscillations in hippocampal slices," Neuropharmacology, vol. 47, no. 3, pp. 381-389, 2004.
48. C. G. Reich, M. A. Karson, S. V. Karnup, L. M. Jones, and B. E. Alger, "Regulation of IPSP theta rhythm by muscarinic receptors and endocannabinoids in hippocampus," Journal of Neurophysiology, vol. 94, no. 6, pp. 4290-4299, 2005.
49. A. I. Gutierrez-Lerma, B. Ordaz, and F. Pena-Ortega, "Amyloid beta peptides differentially affect hippocampal theta rhythms in vitro," International Journal of Peptides, vol. 2013, Article ID 328140, 11 pages, 2013.
50. Y. Ikarashi, Y. Harigaya, Y. Tomidokoro et al. , "Decreased level of brain acetylcholine and memory disturbance in APPsw mice," Neurobiology of Aging, vol. 25, no. 4, pp. 483-490, 2004.
51. M. Klingner, J. Apelt, A. Kumar et al. , "Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β-amyloid plaque pathology," International Journal of Developmental Neuroscience, vol. 21, no. 7, pp. 357-369, 2003.
52. J. H. Kordower, Y. Chu, G. T. Stebbins et al. , "Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment," Annals of Neurology, vol. 49, no. 2, pp. 202-213, 2001.
53. H.-J. Luth, J. Apelt, A. O. Ihunwo, T. Arendt, and R. Schliebs, "Degeneration of β-amyloid-associated cholinergic structures in transgenic APPsw mice," Brain Research, vol. 977, no. 1, pp. 16-22, 2003.
54. C. Babiloni, G. B. Frisoni, M. Pievani et al. , "White matter vascular lesions are related to parietal-to-frontal coupling of EEG rhythms inmild cognitive impairment,"Human BrainMapping, vol. 29, no. 12, pp. 1355-1367, 2008.
55. T. D. R. Cummins, M. Broughton, and S. Finnigan, "Theta oscillations are affected by amnestic mild cognitive impairment and cognitive load," International Journal of Psychophysiology, vol. 70, no. 1, pp. 75-81, 2008.
56. F. Pena-Ortega and R. Bernal-Pedraza, "Amyloid beta peptide slows down sensory-induced hippocampal oscillations," International Journal of Peptides, vol. 2012, Article ID 236289, 8 pages, 2012.
57. C. Babiloni, E. Cassetta, G. Binetti et al. , "Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimers disease," European Journal of Neuroscience, vol. 25, no. 12, pp. 3742-3757, 2007.
58. M. Weiergraber, M. Henry, J. Hescheler, N. Smyth, and T. Schneider, "Electrocorticographic and deep intracerebral EEG recording in mice using a telemetry system," Brain Research Protocols, vol. 14, no. 3, pp. 154-164, 2005.
59. K. Kramer and L. B. Kinter, "Evaluation and applications of radiotelemetry in small laboratory animals," Physiological Genomics, vol. 13, no. 3, pp. 197-205, 2003.
60. R. Kronland-Martinet, J. Morlet, and A. Grossmann, "Analysis of sound patterns through wavelet transforms," International Journal of Pattern Recognition and Artificial Intelligence, vol. 1, no. 2, pp. 273-302, 1987.
61. S. M. Montgomery and G. Buzsaki, "Gamma oscillations dynamically couple hippocampal CA3 and CA1 regions during memory task performance," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 36, pp. 14495-14500, 2007.
62. R. Muller,H. Struck, M. S. P. Ho et al. , "Atropine-sensitive hippocampal theta oscillations aremediated byCaν2. 3 R-type Ca2+ channels," Neuroscience, vol. 205, pp. 125-139, 2012.
63. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44-57, 2009.
64. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists," Nucleic Acids Research, vol. 37, no. 1, pp. 1-13, 2009.
65. T. D. Schmittgen and K. J. Livak, "Analyzing real-time PCR data by the comparative CT method," Nature Protocols, vol. 3, no. 6, pp. 1101-1108, 2008.
66. Y. Hochberg, "Asharper Bonferroni procedure formultiple tests of significance," Biometrika, vol. 75, no. 4, pp. 800-802, 1988.
67. M. A. Burguillos, T. Deierborg, E. Kavanagh et al. , "Caspase signalling controlsmicroglia activation and neurotoxicity," Nature, vol. 472, no. 7343, pp. 319-324, 2011.
68. V. Jelic, S.-E. Johansson, O. Almkvist et al. , "Quantitative electroencephalography inmild cognitive impairment: longitudinal changes and possible prediction of Alzheimers disease," Neurobiology of Aging, vol. 21, no. 4, pp. 533-540, 2000.
69. K. van der Hiele, A. A. Vein, A. van der Welle et al. , "EEG and MRI correlates of mild cognitive impairment and Alzheimers disease," Neurobiology of Aging, vol. 28, no. 9, pp. 1322-1329, 2007.
70. B. Czigler, D. Csikos, Z. Hidasi et al. , "Quantitative EEG in early Alzheimers disease patients-power spectrum and complexity features," International Journal of Psychophysiology, vol. 68, no. 1, pp. 75-80, 2008.
71. V. D. Moretti, M. Pievani, C. Geroldi et al., "EEG markers discriminate among different subgroup of patients with mild cognitive impairment, "American Journal ofAlzheimers Disease and Other Dementias, vol. 25, no. 1, pp. 58-73, 2010.
72. J. Noebels, "A perfect storm: converging paths of epilepsy and Alzheimers dementia intersect in the hippocampal formation," Epilepsia, vol. 52, supplement 1, pp. 39-46, 2011.
73. F. M. LaFerla, B. T. Tinkle, C. J. Bieberich, C. C. Haudenschild, and G. Jay, "The Alzheimers Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice," Nature Genetics, vol. 9, no. 1, pp. 21-30, 1995.
74. R. Lalonde, M. Dumont,M. Staufenbiel, and C. Strazielle, "Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen," Behavioural Brain Research, vol. 157, no. 1, pp. 91-98, 2005.
75. D. Moechars, K. Lorent, B. de Strooper, I. Dewachter, and F. Van Leuven, "Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice," The EMBO Journal, vol. 15, no. 6, pp. 1265-1274, 1996.
76. V. B. Kumar, S. A. Farr, J. F. Flood et al. , "Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice," Peptides, vol. 22, no. 12, pp. 1769-1775, 2000.
77. J. P. Steinbach, U. Muller, M. Leist, Z.-W. Li, P. Nicotera, and A. Aguzzi, "Hypersensitivity to seizures in β-amyloid precursor protein deficient mice," Cell Death and Differentiation, vol. 5, no. 10, pp. 858-866, 1998.
78. Y.-S. Hu, P. Xu, G. Pigino, S. T. Brady, J. Larson, and O. Lazarov, "Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimers disease-linked APPswe/PS1ΔE9 mice," The FASEB Journal, vol. 24, no. 6, pp. 1667-1681, 2010.
79. D. Pandis and N. Scarmeas, "Seizures in alzheimer disease: clinical and epidemiological data," Epilepsy Currents, vol. 12, no. 5, pp. 184-187, 2012.
80. N. C. de Lanerolle, J. H. Kim, R. J. Robbins, and D. D. Spencer, "Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy," Brain Research, vol. 495, no. 2, pp. 387-395, 1989.
81. T. Sutula, G. Cascino, J. Cavazos, I. Parada, and L. Ramirez, "Mossy fiber synaptic reorganization in the epileptic human temporal lobe," Annals of Neurology, vol. 26, no. 3, pp. 321-330, 1989.
82. R. Minkeviciene, J. Ihalainen, T. Malm et al. , "Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice," Journal of Neurochemistry, vol. 105, no. 3, pp. 584-594, 2008.
83. K. Jin, A. L. Peel, X. O. Mao et al. , "Increased hippocampal neurogenesis in Alzheimers disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 343-347, 2004.
84. J. C. Amatniek, W. A. Hauser, C. DelCastillo-Castaneda et al. , "Incidence and predictors of seizures in patients with Alzheimers disease," Epilepsia, vol. 47, no. 5, pp. 867-872, 2006.
85. C. J. Westmark, P. R. Westmark, A. M. Beard, S. M. Hildebrandt, and J. S. Malter, "Seizure susceptibility and mortality in mice that over-express amyloid precursor protein," International Journal of Clinical and Experimental Pathology, vol. 1, no. 2, pp. 157-168, 2008.
86. T. Womelsdorf, J.-M. Schoffelen, R. Oostenveld et al. , "Modulation of neuronal interactions through neuronal synchronization," Science, vol. 316, no. 5831, pp. 1609-1612, 2007.
87. N. McNaughton, M. Ruan, and M.-A. Woodnorth, "Restoring theta-like rhythmicity in rats restores initial learning in the Morris water maze," Hippocampus, vol. 16, no. 12, pp. 1102-1110, 2006.
88. J. Shin, D. Kim, R. Bianchi, R. K. S. Wong, and H.-S. Shin, "Genetic dissection of theta rhythm heterogeneity in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 18165-18170, 2005.
89. B. H. Bland, C. Trepel, S. D. Oddie, and I. J. Kirk, "Intraseptal microinfusion of muscimol: effects on hippocampal formation theta field activity and phasic Theta-ON cell discharges," Experimental Neurology, vol. 138, no. 2, pp. 286-297, 1996.
90. S. D. Berry, P. C. Rinaldi, R. F. Thompson, and M. Verzeano, "Analysis of temporal relations among units and slow waves in rabbit hippocampus," Brain Research Bulletin, vol. 3, no. 5, pp. 509-518, 1978.
91. A. Jeewajee, C. Lever, S. Burton, J. OKeefe, and N. Burgess, "Environmental novelty is signaled by reduction of the hippocampal theta frequency," Hippocampus, vol. 18,no. 4, pp. 340-348, 2008.
92. C. C. Felder, "Muscarinic acetylcholine receptors: signal transduction through multiple effectors," The FASEB Journal, vol. 9, no. 8, pp. 619-625, 1995.
93. H.-M. Huang, H.-C. Ou, and S.-J. Hsieh, "Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons," Neurochemical Research, vol. 25, no. 2, pp. 303-312, 2000.
94. J. B. Kuzmiski, W. Barr, G. W. Zamponi, and B. A. MacVicar, "Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels," Epilepsia, vol. 46, no. 4, pp. 481-489, 2005.
95. C. Tai, J. B. Kuzmiski, and B. A. MacVicar, "Muscarinic enhancement of R-type calcium currents in hippocampal CA1 pyramidal neurons," The Journal of Neuroscience, vol. 26, no. 23, pp. 6249-6258, 2006.
96. J. Shin, G. Gireesh, S.-W. Kim et al. , "Phospholipase C β4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors," The Journal of Neuroscience, vol. 29, no. 49, pp. 15375-15385, 2009.
97. R. Jansen, J. Timmerman, M. Loos et al. , "Novel candidate genes associated with hippocampal oscillations," PLoSONE, vol. 6, no. 10, Article ID e26586, 2011.